Skip to main content

Table 1 Clinical characteristics

From: Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis

Baseline demographics Discovery cohort Validation cohort 1 Validation cohort 2
lcSSc-PAH lcSSc-no PAH lcSSc-PAH lcSSc-no PAH lcSSc-PAH lcSSc-no PAH
Age (year) n = 13 n = 16 n = 23 n = 12 n = 11 n = 18
 Mean (SD) 65 (7.4) 50 (14) 66 (8.6) 54 (17.8) 66 (9.4) 62 (8.5)
  Median (range) 65 (56–81) 57 (25–70) 64 (52–85) 52 (26–76) 66 (52–81) 63 (46–79)
Sex
 Female, % (n) 92% (12) 87.5% (14) 83% (19) 92% (11) 100% (11) 83% (15)
  Male,% (n) 8% (1) 12.5% (2) 17% (4) 8% (1) 0% (0) 17% (3)
mPAP (mmHg)
 Mean (SD) 46 (9.1) 42 (12.3) 40 (10.8)
 Median (range) 45 (34–68) 43 (26–69) 42 (25–54)
mPCWP (mmHg)
 Mean (SD) 10 (2.7) 10 (4.3) 10 (3.2)
 Median (range) 11 (4–14) 11 (1–15) 9 (5–15)
PVR (Woods units)
 Mean (SD) 9 (4.9) 8 (5.3) 8 (4.1)a
 Median (range) 8 (5–24) 6 (3–27) 7 (3–13)a
ILD (Dx by HRCT)
 Positive, % (n) 7% (1) 13% (3) 0% (0)
 Negative, % (n) 83% (12) 87% (20) 100% (11)
Treatment
 Treated, % (n) 0% (0) 48% (11) 100% (11)
 Untreated, % (n) 100% (13) 52% (12) 0% (0)
BNP (pg/mL)
 Mean (SD) 261 (313) 411 (494)
 Median (range) 140 (42–1054) 148 (12–1630)
Date of sample
 At time of RHC, % (n) 100% (13) 91% (21) 36% (4)
  1. aMissing values
  2. BNP, brain natriuretic peptide; lcSSc-PAH, limited cutaneous systemic sclerosis pulmonary arterial hypertension; ILD, interstitial lung disease; mPAP, mean pulmonary artery pressure; mPCWP, mean pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RHC, right heart catheterization